Viva Biotech HoldingsFRA:VB0 +2.59%47 Days Payable is 61.64 as of Dec. 2025, which is 15% below its 10-year median of 72.64. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 705 Biotechnology companies, Viva Biotech Holdings ranks worse than 57.59% on this metric.
Viva Biotech Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Viva Biotech Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Days Payable of 61.64 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viva Biotech Holdings and its competitors. This is 15% below median its historical median of 72.64. Over the past decade, Viva Biotech Holdings' Days Payable has ranged from 13.46 to 140.94. According to the industry distribution chart, Viva Biotech Holdings ranks #406 out of 705 companies in the Biotechnology industry, placing it in the top 57.6%.
Is Viva Biotech Holdings' Days Payable too high?
Viva Biotech Holdings' current Days Payable of 61.64 is 15% below median its 10-year median of 72.64. Over the past 10 years, this metric has ranged from a low of 13.46 to a high of 140.94. The Biotechnology industry median Days Payable is 113.36. Viva Biotech Holdings' value of 61.64 is 45.6% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #406 out of 705 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #406 out of 705 companies for Days Payable. This places Viva Biotech Holdings in the lower half of its industry. The industry median Days Payable is 113.36. Viva Biotech Holdings' value of 61.64 is 45.6% below this benchmark. Historically, Viva Biotech Holdings' own Days Payable has ranged from 13.46 to 140.94 over the past decade. While the company's 10-year median is 72.64 vs. the industry median of 113.36, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Days Payable of 61.64 is 45.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Days Payable is 61.64, which is 15% below median its own 10-year median of 72.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Days Payable is 61.64, which is 15% below median its 10-year median of 72.64 and 45.6% below the Biotechnology industry median of 113.36. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Days Payable is 61.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Days Payable: 61.64 (15% below median its 10-year median of 72.64)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
Industry Position: 45.6% below the Biotechnology median (#406 of 705)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
